Harrow

Harrow HROW Stock

$32.05   8.572485%
Add to favorites
Market Cap
$1.20B
LOW - HIGH [24H]
$29.20 - $32.40
VOLUME [24H]
$187.74K
P/E Ratio
0
Earnings per share
-$0.76
ISIN
US4158581094
Price   Prediction

Harrow Price Chart

Sorry, that's all we've gotfor now...

Harrow (HROW) stock price today is 32.05 USD on Tech Market Middle (+8.57% on the day). Updated .

Harrow HROW Financial and Trading Overview

Harrow stock price 32.05 USD
Previous Close 29.09 USD
Open 29 USD
Bid 28.48 USD x 200
Ask 51.2 USD x 200
Day's Range 28.75 - 29.7 USD
52 Week Range 25.76 - 54.85 USD
Volume 452.8K USD
Avg. Volume 611.03K USD
Market Cap 1.11B USD
Beta (5Y Monthly) 0.167
PE Ratio (TTM) N/A
EPS (TTM) -0.76 USD
Forward Dividend & Yield N/A (0%)
Ex-Dividend Date N/A
1y Target Est 62.25 USD

HROW Valuation Measures

Enterprise Value 1.33B USD
Trailing P/E N/A
Forward P/E 15.786097
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm) 3.6536453
Price/Book (mrq) 37.943447
Enterprise Value/Revenue 4.391
Enterprise Value/EBITDA 84.588

Trading Information

Harrow Stock Price History

Beta (5Y Monthly) 0.167
52-Week Change -25.45%
S&P500 52-Week Change 10.51%
52 Week High 54.85 USD
52 Week Low 25.76 USD
50-Day Moving Average 30.42 USD
200-Day Moving Average 37.37 USD

HROW Share Statistics

Avg. Volume (3 month) 611.03K USD
Avg. Daily Volume (10-Days) 863.97K USD
Shares Outstanding 37.53M
Float 28.28M
Short Ratio 12.05
% Held by Insiders 17.98%
% Held by Institutions 61.50%
Shares Short 7.09M
Short % of Float 21.03%
Short % of Shares Outstanding 18.89%

Dividends & Splits

Trailing Annual Dividend Rate 0
Trailing Annual Dividend Yield 0%
5 Year Average Dividend Yield N/A
Payout Ratio 0
Last Split Factor 1:5

Financial Highlights

Fiscal Year

Fiscal Year Ends December 31, 2025
Most Recent Quarter (mrq) September 30, 2026
Next Fiscal Year End December 31, 2026

Profitability

Profit Margin -9.39%
Operating Margin (ttm) -1.98%
Gross Margin 73.51%
EBITDA Margin 5.19%

Management Effectiveness

Return on Assets (ttm) -0.93%
Return on Equity (ttm) -75.47%

Income Statement

Revenue (ttm) 303.25M USD
Revenue Per Share (ttm) 8.12 USD
Quarterly Revenue Growth (yoy) 38.60%
Gross Profit (ttm) 222.94M USD
EBITDA 15.74M USD
Net Income Avi to Common (ttm) -28489000 USD
Diluted EPS (ttm) -0.76
Quarterly Earnings Growth (yoy) 856.60%

Balance Sheet

Total Cash (mrq) 76.81M USD
Total Cash Per Share (mrq) 2.05 USD
Total Debt (mrq) 300.86M USD
Total Debt/Equity (mrq) 1043.41 USD
Current Ratio (mrq) 2.288
Book Value Per Share (mrq) 0.778

Cash Flow Statement

Operating Cash Flow (ttm) -18952000 USD
Levered Free Cash Flow (ttm) -34198876 USD

Profile of Harrow

Country United States
State TN
City Nashville
Address 1A Burton Hills Boulevard
ZIP 37215
Phone 615 733 4730
Website https://www.harrow.com
Industry Drug Manufacturers - Specialty & Generic
Sector(s) Healthcare
Full Time Employees 373

Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products in the United States. It operates through Branded and ImprimisRx segments. The company offers ImprimisRx, an ophthalmology-focused compounded medications. It also provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic solutions, including IOPIDINE, VEVYE, and ZERVIATE, as well as BYQLOVI; MAXITROL eye drops; ILEVRO and NEVANAC, a non-steroidal and anti-inflammatory eye drop for pain and inflammation associated with cataract surgery; BYOOVIZ, a LUCENTIS biosimilar indicated for the treatment of patients with Neovascular (Wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), and myopic choroidal neovascularization (mCNV); VIGAMOX, a fluoroquinolone antibiotic eye drop for the treatment of bacterial conjunctivitis; OPUVIZ, an EYLEA biosimilar indicated for the treatment of patients with Wet AMD, macular edema following RVO, diabetic macular edema (DME), and diabetic retinopathy (DR); MAXIDEX and FLAREX, a steroid eye drop for steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe and the eye; TRIESENCE, a steroid injection for the treatment of ophthalmic diseases and for visualization during vitrectomy; and NATACYN, a sterile, antifungal drug for the treatment of fungal blepharitis, conjunctivitis, and keratitis. In addition, it offers TOBRADEX ST, a tobramycin and dexamethasone ophthalmic suspension; VERKAZIA cyclosporine ophthalmic emulsion; NEVANAC, a non-steroidal, anti-inflammatory eye drop; and FRESHKOTE preservative free (PF) is a lubricant eye drop. The company was formerly known as Harrow Health, Inc. and changed its name to Harrow, Inc. in September 2023. Harrow, Inc. was founded in 1998 and is headquartered in Nashville, Tennessee.

Q&A For Harrow Stock

What is a current HROW stock price?

Harrow HROW stock price today per share is 32.05 USD.

How to purchase Harrow stock?

You can buy HROW shares on the Tech Market Middle exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for Harrow?

The stock symbol or ticker of Harrow is HROW.

Which industry does the Harrow company belong to?

The Harrow industry is Drug Manufacturers - Specialty & Generic.

How many shares does Harrow have in circulation?

The max supply of Harrow shares is 37.53M.

What is Harrow Price to Earnings Ratio (PE Ratio)?

Harrow PE Ratio is now.

What was Harrow earnings per share over the trailing 12 months (TTM)?

Harrow EPS is -0.76 USD over the trailing 12 months.

Which sector does the Harrow company belong to?

The Harrow sector is Healthcare.

Harrow HROW included in indexes

Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
us US Tech Composite IXIC US 24356.87 USD —
+0.12
2.55B USD — 24268.03 USD — 24538.78 USD — — 2.55B USD —
us US Tech Capital Market Composite RCMP US 108.96 USD —
+0.25
— — 108.35 USD — 109.95 USD — — — —
us Stlmt ID US Tech Biotechnology NBX US 4000.62 USD —
-1.26
— — 3927.42 USD — 4148.65 USD — — — —
us US Tech Global Market Composite NQGM US 1839.09 USD —
+0.18
— — 1832.56 USD — 1855.92 USD — — — —
us US Tech Biotechnology NBI US 6986.34 USD —
-0.45
— — 6959.96 USD — 7076.43 USD — — — —
us US Tech Health Care IXHC US 1327.34 USD —
-0.42
— — 1322.85 USD — 1342.46 USD — — — —
$2.18T
Total marketcap
$69.46B
Total volume
BTC 58.15%   •   ETH 9.90%
Dominance
Select currency